In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ProSkelia SAS

Latest From ProSkelia SAS

Deals Shaping the Medical Industry (1/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

Spin-Out Step-Ups Reflect Bulk, Not Risk

An analysis of a group of Big Pharma and big biotech spin-outs, which tend to raise more private money than their build-from-scratch bretheren, shows that while these firms are certainly heftier--and often considered better equiped to succeed in the public markets--their pre-money step-ups are in the end, nothing special.

BioPharmaceutical Strategy

Graffinity/MyoContract: Two Problems, One Solution

By merging with Swiss product development group MyoContract, Germany's Graffinity addresses its two key issues at once: a lack of products, and poor prospects for a viable listing in its home market. Europe's industry needs more such deals, but making them happen isn't easy.

BioPharmaceutical Business Strategies

Europe's Flavors of Sustainable BioPharma

Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.

BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Pharmaceuticals